<div id="readability-page-1"><div><p>Sept 25 (Reuters) - Intellia Therapeutics Inc:</p><ul><li>Intellia Therapeutics announces positive longer-term phase 1 data for nexiguran ziclumeran (Nex-Z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy</li><li>   Intellia Therapeutics Inc - one dose of Nex-Z shows durable TTR reductions of at least 90% through three years</li><li>   Intellia Therapeutics Inc - favorable safety data with no new drug-related events</li><li>   Intellia Therapeutics Inc - phase 3 Magnitude-2 trial enrollment expected by first half 2026</li></ul></div></div>

NTLA

<p>Sept 25 (Reuters) - Intellia Therapeutics Inc:Intellia Therapeutics announces positive longer-term phase 1 data for nexiguran ziclumeran (Nex-Z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy Intellia Therapeutics Inc - one dose of Nex-Z shows durable TTR reductions of at least 90% through three years Intellia Therapeutics Inc - favorable safety data with no new drug-related events Intellia Therapeutics Inc - phase 3 Magnitude-2 trial enrollment expected by first half 2026</p>

Intellia 治療公司稱，Nex-Z 單劑在三年內可持續降低 TTR 至少 90%